Key result
Treatment with oral tetrahydrobiopterin significantly reduced systolic blood pressure from 146 mmHg to 132 mmHg (P<0.05) and decreased vascular superoxide production in mice with DOCA-salt hypertension.
Why the study?
Does oral tetrahydrobiopterin reduce vascular ROS production, increase NO production, and blunt the increase in blood pressure in mice with DOCA-salt hypertension?
Does oral tetrahydrobiopterin reduce vascular ROS production, increase NO production, and blunt the increase in blood pressure in mice with DOCA-salt hypertension?
Absolute Event Rate: 132% vs 146%
p-value: p=<0.05
Oral tetrahydrobiopterin prevents the uncoupling of endothelial NO synthase, reducing vascular ROS production and blunting blood pressure increases in a mouse model of hypertension.
No takes yet. Share an insight, caveat, or question.
Should not alter hypertension management; leaves open translation of tetrahydrobiopterin effects to human disease.
Landmesser et al. (2003) studied DOCA-salt hypertension. Tetrahydrobiopterin vs. Untreated DOCA-salt was evaluated on Systolic blood pressure at 30 days (p=<0.05). Treatment with oral tetrahydrobiopterin significantly reduced systolic blood pressure from 146 mmHg to 132 mmHg (P<0.05) and decreased vascular superoxide production in mice with DOCA-salt hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: